Shankar Balasubramanian

Co-Founder at Cambridge Epigenetix Ltd.

Shankar Balasubramanian

Shankar Balasubramanian

Co-Founder at Cambridge Epigenetix Ltd.

Biography

Founder of Solexa, Inc. and Cambridge Epigenetix Ltd., Shankar Balasubramanian is on the board of Cambridge Epigenetix Ltd. and Professor at the University of Cambridge.

Overview
Career Highlights

Cambridge Epigenetix Ltd.
Solexa, Inc.

RelSci Relationships

470

Number of Boards

1

Relationships
RelSci Relationships are individuals Shankar Balasubramanian likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Cambridge Epigenetix Ltd.

Relationship likelihood: Strong

Chief Executive Officer at Syncona Ltd.

Relationship likelihood: Strong

Advisor at Avelas Biosciences, Inc.

Relationship likelihood: Strong

General Partner at GV Management Co. LLC

Relationship likelihood: Strong

Chief Executive Officer at Start Codon

Relationship likelihood: Strong

Partner at Sequoia Capital

Relationship likelihood: Strong

Co-Founder & Managing Partner at New Science Ventures LLC

Relationship likelihood: Strong

Chief Executive Officer at Cambridge Epigenetix Ltd.

Relationship likelihood: Strong

Founder & Managing Partner at Ahren Innovation Capital LLP

Relationship likelihood: Strong

Assistant Professor at Hofstra University

Relationship likelihood: Strong

Paths to Shankar Balasubramanian
Potential Connections via
Relationship Science
You
Shankar Balasubramanian
Co-Founder at Cambridge Epigenetix Ltd.
Career History
Co-Founder
2012 - Current

Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom.

Professor
Current

The University of Cambridge (informally known as Cambridge University or Cambridge) is a public research university located in Cambridge, United Kingdom. It is the second-oldest university in the English-speaking world (after the University of Oxford), and the seventh-oldest in the world.

Founder
Prior

Solexa, Inc. used to create DNA cloning and analyses technologies to enhance gene discovery. It also used to provide genomics, genetics and proteomics technologies to assist the customers in the field of pharmaceutical and agriculture. The company was located in Hayward, CA.

Investments
Details Hidden

Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom.

Other Affiliations

Shankar Balasubramanian is affiliated with Cambridge Epigenetix Ltd., University of Cambridge, Solexa, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Shankar Balasubramanian. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Shankar Balasubramanian's profile does not indicate a business or promotional relationship of any kind between RelSci and Shankar Balasubramanian.